No abstract

Aim of the study – the development of a method for obtaining a tumor xenograft model by a subcutaneous transplantation of a porous metal scaffold populated with cultured human lung carcinoma cells. Material and methods. The study included 14 athymic male Balb c/nude mice aged 8-90 weeks, weighing 20-24 g. All animals received injections with cultured human A549 lung carcinoma cells subcutaneously into the right anterolateral area of the back. In animals of the main group (gr.1, n=4), scaffolds with a pore diameter of 0.5 mm made of titanium-aluminum-vanadium alloy using an industrial 3D printer served as carriers of tumor cells. Scaffolds were seeded with 3 million A549 culture cells, and were implanted into the recipient animals after the 7-day incubation. Results were compared with the results of the tumor culture transplantation with Matrigel (100 mcL) in two groups of animals with varying cell suspension dosages: the maximum vaccination dose for in vivo (10×106 cells per mouse, gr.2, n=5) and half the maximum dose (5×106 respectively, gr.3, n=5). Then, the dynamics of tumor growth in the groups of experimental mice was monitored for 55 days: xenograft volumes were calculated using the Shrek’s formula for an ellipsoid. At the end of the experiment, the animals were euthanized by cervical dislocation. Results. Monitoring of the dynamics of xenograft volumes demonstrated the maximal values in mice with implanted scaffolds. The slowest xenograft growth was registered in animals with the maximum vaccination dose of tumor cells with Matrigel. Histological study showed that tumor material obtained from all animals corresponded to A549 lung carcinoma. Conclusions. Porous metal scaffolds, previously incubated with A549 culture cells and implanted subcutaneously in athymic Balb c/nude mice, allows obtaining rapidly growing xenografts with histologically confirmed correspondence to the original tumor.

Aim. To study the diagnostic characteristics of the rapid test for qualitative simultaneous determination of cardiac fatty acid-binding protein (FABPs) and cardiac troponin I (cTnI) CARD-INFO 1+1 in patients with acute coronary syndrome (ACS).Material and methods. The study included 168 patients undergoing inpatient treatment after ACS, with typical anginal pain lasting at least 20 minutes occurred in the previous 1-24 hours. In addition to routine diagnostic procedures, on admission, we determined FABPs and cTnI concentrations using the high-quality immunochromatographic rapid test CARD-INFO 1 1 (OOO CARDIO-Plus, Russia).Results. The sensitivity of the CARD-INFO 1+1 rapid test was 88,1%, specificity — 89,8%, diagnostic accuracy — 88,7%. The indicators of the diagnostic effectiveness of CARD-INFO 1+1 test in patients with STE-ACS and NSTE-ACS did not significantly differ (p>0,05). The sensitivity of the rapid test reached a maximum in the period from 3 to 6 hours from the onset of pain. Compared with the determination of cTnI performed on admission to the hospital, a higher sensitivity of the CARD-INFO 1+1 test was revealed in patients with STE-ACS (87,7% vs 75,3%; p=0,044), in the first 1-3 hours after the beginning of clinical manifestations (86,8% vs 60,5%; p=0,041) and in the entire sample as a whole (88,1% vs 77,1%; p=0,033), with comparable specificity (89,8% and 93,2%, respectively; p=0,741).Conclusion. Qualitative immunochromatographic CARD-INFO 1+1 rapid test for the simultaneous determination of the content of FABPs and cTnI I is highly effective in the diagnosis of various forms of ACS. The highest diagnostic characteristics of the test were observed in patients in the early stages of the disease (the first 1-6 hours after the onset of pain). Carrying out the CARD-INFO 1+1 test revealed 12 MI cases more (11%) than the first determination of cTnI. Further studies will clarify the place of this technique in the modern algorithm for the management of patients with ACS and evaluate the possibility of using the rapid test in predicting the course of the disease.

No abstract